Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B.
Kramkimel N, et al. Among authors: regnier rosencher e.
Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8.
Target Oncol. 2016.
PMID: 26208946